Cargando…
Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre–Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial
IMPORTANCE: Pre–heart failure with preserved ejection fraction (pre-HFpEF) is common and has no specific therapy aside from cardiovascular risk factor management. OBJECTIVE: To investigate the hypothesis that sacubitril/valsartan vs valsartan would reduce left atrial volume index using volumetric ca...
Autores principales: | Ledwidge, Mark, Dodd, Jonathan D., Ryan, Fiona, Sweeney, Claire, McDonald, Katherine, Fox, Rebecca, Shorten, Elizabeth, Zhou, Shuaiwei, Watson, Chris, Gallagher, Joseph, McVeigh, Niall, Murphy, David J., McDonald, Kenneth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996460/ https://www.ncbi.nlm.nih.gov/pubmed/36884247 http://dx.doi.org/10.1001/jamacardio.2023.0065 |
Ejemplares similares
-
Sacubitril‐Valsartan in a routine community population: attention to volume status critical to achieving target dose
por: Pharithi, Rebabonye B., et al.
Publicado: (2020) -
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
por: Selvaraj, Senthil, et al.
Publicado: (2021) -
The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020) -
Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021) -
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)